We’re excited to support Julian Abhari (CTO), Dani Marques (CEO), and the team at SkinCheck through the Arionkoder Reshape Health Grants program.
SkinCheck is building a more inclusive approach to skin cancer detection. Their AI-driven app is designed to accurately identify lesions on all skin tones — addressing a long-standing gap in dermatology.
We’re proud to help them advance early detection that works for everyone.
See the video transcript below:
Hello. I’m Julian Abhari. I’m the cofounder and CTO at Skin Check.
So at least one in every five Americans, will be diagnosed with skin cancer before the age of 70. But what makes matters worse is, contrary to misconception, skin cancer is far more lethal for people of color. In fact, there’s a thirty percent higher death rate for black men from skin cancers like melanoma more than any other demographic. But melanoma is a type of skin cancer that can become as lethal, and it’s just as short as six weeks, where the average wait time to get a skin cancer screening is of fourteen weeks. SkinCheck is a solution that enables patients to expedite their access to treatment and empowers healthcare providers to intervene when necessary.
Our AI technology for skin cancer detection is what we’re currently, building as a medical device. One that, our clinical studies, are seeking to prove the validation of primary care providers being able to intervene when necessary and detect concerning skin lesions from their patients. And what makes our technology so unique is, of course, the fact that it was built to work for all skin tones, and now it’s become actually the first visual skin cancer detector that works for all skin tones. And this technology is one that throughout our SkinCheck platform, whether user or, medical professional, is very much focused on optimizing and improving our technology, collecting data, in order to, make sure that the accuracy, sensitivity, and specificity is on par, allowing us to achieve FDA approval.